SCHEMBL20420745

SCHEMBL20420745

COc1ccc2c(-c3ccc(-c4ccc(C)cc4)s3)cc(=O)oc2c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAOB P27338 4/20 0.55
▸ HPGD P15428 6/20 0.54
▸ ALDH1A1 P00352 5/20 0.54
▸ KDM4E B2RXH2 5/20 0.54
▸ HSD17B10 Q99714 1/20 0.54
▸ NOD2 Q9HC29 1/20 0.53
▸ CA12 O43570 2/20 0.50
▸ CA9 Q16790 2/20 0.50
▸ RECQL P46063 1/20 0.50
▸ LMNA P02545 1/20 0.50
▸ RAB9A P51151 1/20 0.47
▸ CA1 P00915 1/20 0.47
▸ CA2 P00918 1/20 0.47
▸ CA3 P07451 1/20 0.47
▸ CA4 P22748 1/20 0.47
▸ CA5A P35218 1/20 0.47
▸ CA7 P43166 1/20 0.47
▸ CA14 Q9ULX7 1/20 0.47
▸ CA5B Q9Y2D0 1/20 0.47
▸ CYP2D6 P10635 3/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20420750 0.89 CA1 (0.52) MAOBHPGDALDH1A1KDM4EHSD17B10
SCHEMBL20420776 0.88 HPGD (0.55) MAOBHPGDALDH1A1KDM4EHSD17B10
SCHEMBL20420780 0.84 CA12 (0.52) HPGDALDH1A1KDM4EHSD17B10NOD2
SCHEMBL20420772 0.84 ALDH1A1 (0.49) HPGDALDH1A1KDM4EHSD17B10NOD2
SCHEMBL20420786 0.83 ALDH1A1 (0.52) MAOBHPGDALDH1A1KDM4EHSD17B10
SCHEMBL20420790 0.82 CYP2D6 (0.56) HPGDALDH1A1KDM4EHSD17B10NOD2
SCHEMBL20420758 0.81 KDM4E (0.55) HPGDALDH1A1KDM4EHSD17B10NOD2
SCHEMBL20420799 0.81 CA12 (0.49) MAOBALDH1A1CA12CA9LMNA
SCHEMBL20428335 0.81 APP (0.52) HPGDALDH1A1KDM4EHSD17B10NOD2
SCHEMBL20420733 0.81 MAOB (0.64) MAOBHPGDALDH1A1KDM4EHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-108349959-B 4-substituted coumarin derivative and preparation method and application thereof 成都赜灵生物医药科技有限公司 2021-11-16 — — CN disclosed
US-10544134-B2 4-substituted coumarin derivatives and preparation methods and uses thereof GUIZHOU BAILING GROUP PHARMACEUTICAL CO., LTD. (CN) 2020-01-28 — — US disclosed
US-10544134-B2 4-substituted coumarin derivatives and preparation methods and uses thereof GUIZHOU BAILING GROUP PHARMACEUTICAL CO., LTD. (CN) 2020-01-28 — — US disclosed
US-20180282315-A1 4-SUBSTITUTED COUMARIN DERIVATIVES AND PREPARATION METHODS AND USES THEREOF CHENGDU ZENITAR BIOMEDICAL TECHNOLOGY CO., LTD. (CN) 2018-10-04 — — US disclosed
EP-3354648-A1 4-SUBSTITUED COUMARIN DERIVATIVE, AND PREPARATION METHOD AND USE THEREOF Guizhou Bailing Group Pharmaceutical Co., Ltd. (CN) 2018-08-01 — — EP disclosed
EP-3354648-A1 4-SUBSTITUED COUMARIN DERIVATIVE, AND PREPARATION METHOD AND USE THEREOF Guizhou Bailing Group Pharmaceutical Co., Ltd. (CN) 2018-08-01 — — EP disclosed
CN-108349959-A The coumarin derivative and its preparation method and application of 4 substitutions 贵州百灵企业集团制药股份有限公司 2018-07-31 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10544134-B2 4-substituted coumarin derivatives and preparation methods and uses thereof MAP4, TUBA3C, ABCC1 MAOB 2670/4885HPGD 2933/4885ALDH1A1 725/4885
US-20180282315-A1 4-SUBSTITUTED COUMARIN DERIVATIVES AND PREPARATION METHODS AND USES THEREOF MAP4, TUBA3C, ABCC1 MAOB 2670/4885HPGD 2933/4885ALDH1A1 725/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback